Review Article

American Journal of Clinical Dermatology

, Volume 11, Supplement 1, pp 3-9

First online:

Etanercept: An Evolving Role in Psoriasis and Psoriatic Arthritis

  • Srdjan ProdanovichAffiliated withFlorida Academic Dermatology Centers
  • , Carlos RicottiAffiliated withFlorida Academic Dermatology Centers
  • , Brad P. GlickAffiliated withFlorida Academic Dermatology Centers
  • , Luca InverardiAffiliated withFlorida Academic Dermatology Centers
  • , Craig L. LeonardiAffiliated withFlorida Academic Dermatology Centers
  • , Francisco KerdelAffiliated withFlorida Academic Dermatology Centers

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access

Abstract

Tumor necrosis factor alpha (TNFα) plays a key pathophysiological role in psoriasis and psoriatic arthritis (PsA). Recent interest has thus focused on the clinical potential of TNFα antagonists (e.g. etanercept) in these settings. In psoriasis, several large pooled analyses and well-designed clinical trials documented the significant clinical efficacy and generally favorable tolerability of etanercept for up to 96 weeks. Similarly, in PsA, a large phase III trial showed that, etanercept significantly reduced arthritic symptoms and inhibited radiographic disease progression; sustained clinical benefit was again evident for up to 2 years. Etanercept is at the forefront of psoriatic disease management, and continued evolution and evaluation of the compound–for example, in detailed comparative studies and economic analyses—is likely to confirm a key role for etanercept in the treatment of psoriasis and PsA.